<DOC>
	<DOCNO>NCT01182441</DOCNO>
	<brief_summary>This prospective , randomize , multicenter study provide additional information safety efficacy WATCHMAN LAA Closure Technology . The PREVAIL study amend initiate prospective , non-randomized continue access study title `` Continued Access PREVAIL ( CAP2 ) '' collect additional information safety efficacy WATCHMAN LAA closure technology . The study estimate enroll initial cohort 300 subject maximum 1500 subject , 60 investigational site U.S .</brief_summary>
	<brief_title>Evaluation WATCHMAN LAA Closure Device Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Key Paroxysmal , persistent permanent nonvalvular AF Eligible longterm warfarin therapy Eligible come warfarin therapy Calculated CHADS2 score 2 great . Also patient CHADS2 score 1 may include follow apply : Female age 75 old Baseline LVEF â‰¥ 30 &lt; 35 % Aged 6574 diabetes coronary artery disease Aged 65 great congestive heart failure Key Contraindicated/allergic aspirin Indicated clopidogrel therapy take clopidogrel within 7 day prior enrollment History atrial septal repair ASD/PFO device Implanted mechanical valve prosthesis NYHA Class IV CHF Resting heart rate &gt; 110 bpm Participated previously PROTECT AF CAP Registry study Key Echo LVEF &lt; 30 % Existing pericardial effusion &gt; 2mm High risk PFO Significant mitral valve stenosis Complex atheroma mobile plaque descend aorta and/or aortic arch Cardiac tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>stroke</keyword>
	<keyword>TIA</keyword>
	<keyword>trans ischemic attack</keyword>
	<keyword>warfarin</keyword>
	<keyword>Coumadin</keyword>
</DOC>